E-therapeutics Plc is a UK-based company focused on drug discovery. The core of its work involves a sophisticated computational platform that employs in-silico screening and unique network models to identify and predict which compounds or biological targets can effectively alter relevant biological processes. Furthermore, the company is advancing an RNA interference (RNAi) platform designed for highly specific gene silencing.